Company Filing History:
Years Active: 2018-2024
Title: Youngho Ko: Innovator in Fibrosis and Respiratory Disease Treatment
Introduction
Youngho Ko is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of medical research, particularly in the development of innovative treatments for fibrosis and respiratory diseases. With a total of 3 patents, his work is paving the way for new therapeutic approaches.
Latest Patents
Youngho Ko's latest patents include groundbreaking inventions such as an amphiregulin gene-specific double-stranded oligonucleotide and a composition for preventing and treating fibrosis-related diseases and respiratory diseases. This invention focuses on a double-stranded oligonucleotide that can efficiently inhibit amphiregulin expression. It comprises a sequence in the form of RNA/RNA, DNA/DNA, or DNA/RNA hybrid, along with nanoparticles that enhance the delivery of the oligonucleotide for therapeutic use. Another notable patent involves a double-stranded oligo RNA targeted to amphiregulin, which is designed to improve the delivery of siRNA specific for fibrosis or respiratory disease-related genes. This innovative structure allows for effective treatment options for patients suffering from these conditions.
Career Highlights
Youngho Ko is associated with Bioneer Corporation, a company known for its advancements in biotechnology and pharmaceuticals. His work at Bioneer has been instrumental in developing novel therapeutic solutions that address critical health issues.
Collaborations
Some of his notable coworkers include Pyoung Oh Yoon and Han Oh Park, who have collaborated with him on various projects aimed at enhancing the efficacy of treatments for fibrosis and respiratory diseases.
Conclusion
Youngho Ko's contributions to medical research and innovation are significant, particularly in the realm of fibrosis and respiratory disease treatment. His patents reflect a commitment to advancing healthcare solutions that can improve patient outcomes.